CAS: 10035-04-8; Calcium Chloride Dihydrate

专利信息

专利号:WO-2024165611-A1
优先权日:2023-02-07
标题:Production of a disaccharide and/or milk oligosaccharide by a cell with reduced synthesis of udp-glcnac
发明人：BEAUPREZ JOERI; DECOENE THOMAS; VERCAUTEREN ANNELIES
权利人:INBIOSE NV
摘要:The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The invention provides a cell for production of a disaccharide and/or an oligosaccharide like a milk oligosaccharide wherein synthesis of UDP-N-acetylglucosamine in said cell is rendered less functional. The invention further provides use of said cell in a cultivation or incubation. The invention also describes methods for the production of a disaccharide and/or an oligosaccharide like a milk oligosaccharide using said cell as well as the purification of said disaccharide and/or oligosaccharide like a milk oligosaccharide.

专利号:US-11390890-B2
优先权日:2015-02-15
标 题:Dibasic organic acid producing strain and preparation and application of same
发明人：TIAN CHAOGUANG; LI JINGEN; LONG CHUANNAN; SUN TAO; LIN LIANGCAI; XU JING; LIU QIAN; JI JINGXIAO; SUN WENLIANG; MA YANHE
权利人:TIANJIN INST IND BIOTECHNOLOGY CAS
摘要:Provided are an engineered strain for synthesizing a dibasic organic acid and preparation and application of same. The engineered strain introduces or up-regulates expression of a positive regulator gene for synthesis of a dibasic organic acid, and/or down-regulates expression of a negative regulator gene for synthesis of a dibasic organic acid, as compared with the origin strain of the engineered strain, the producing capability for producing the dibasic organic acid is improved. The dibasic organic acid comprises malic acid, succinic acid, fumaric acid, oxaloacetic acid, glutaric acid, and adipic acid; the expression product of the positive regulator gene comprises aspartate aminotransferase, glutamic acid-aspartate transporter, C4-dicarboxylic acid transporter, pyruvate carboxylase and malate dehydrogenase, glucose transporter; the expression product of the negative regulatory gene comprises succinyl-CoA synthase, and malic acid-alpha ketoglutarate transporter, and the original strain comprises Myceliophthora thermophila, Thielavia terrestris, Aspergillus , and Rhizopus.

专利号:US-2025108336-A1
优先权日:2022-05-13
标题:Polymer surface for conductive membranes and methods of making thereof
发明人：CORONELL NIETO ORLANDO; ZHANG WEI
权利人:UNIV NORTH CAROLINA CHAPEL HILL
摘要:Electrically conductive membranes (ECMs) have been demonstrated in the literature as a promising tool to enhance the performance of membrane-based water/wastewater treatment technologies. Membrane surface functionalization with “activeâ€? conductive materials is a direct and effective approach to obtain membranes with electrically conductive properties. However, a general strategy that could be utilized to fabricate ECMs using any types of commercial membrane (e.g., reverse osmosis, nanofiltration, ultrafiltration, and microfiltration) as a support or any type of conductive material as ‘active material’ is not available yet. To address this need, the subject matter described herein is a facile and low-cost polyethyleneimine/glutaraldehayde-based method for synthesis of electrically conductive membranes starting from a broad range of commercial membranes (i.e., SWC4+, ESPA3, NF 270, PSf 20 KDa, and 0.1 μm PVDF membranes) by using graphite or other conductive materials, including but not limited to, carbon nanotubes, activated charcoal, reduced graphene oxide, and siler nanoparticles.

专利号:US-11603319-B2
优先权日:2017-12-01
标 题:Synthesis method for producing a calcium zirconate-containing material and batch and coarse ceramic refractory product having a pre-synthesized calcium zirconate-containing granular material
发明人：JANSEN HELGE; JAHN CONSTANTIN; ANEZIRIS CHRISTOS GEORGIOS
权利人:REFRATECHNIK HOLDING GMBH
摘要:A synthesis method for producing a refractory oxide-ceramic material of CaZrO 3 , in particular in the form of a refractory granular material that is preferably mechanically comminuted, in particular crushed and/or ground, as well as to a batch and a coarse ceramic, shaped or unshaped, refractory product containing at least one pre-synthesized refractory calcium zirconate-containing granular material.

专利号:US-11326192-B2
优先权日:2017-07-18
标 题:Variant of oleaginous yeast and its use for the production of lipids
发明人：RODIGHIERO VALENTINA; FRANZOSI GIULIANA; COMPAGNO CONCETTA; CAPUSONI CLAUDIA
权利人:VERSALIS SPA
摘要:The present invention relates to a variant of oleaginous yeast of the species Trichosporon oleaginosus characterized by mutations affecting cell wall synthesis that change the morphology thereof with respect to the wild-type strain of the same species. In particular, thanks to said mutations, cell aggregates are formed which, with respect to the wild-type strain of the same species, lower the viscosity of the culture broth, are more easily separable therefrom and thus make their recovery easier. Said variant of oleaginous yeast of the species Trichosporon oleaginosus is also characterized by yields of oleaginous cellular biomass and intracellular accumulation of lipids that are similar or even higher than those of the wild-type strain. Further, the present invention relates to a process for the production of lipids through said variant of oleaginous yeast of the species Trichosporon oleaginosus . The lipids thus obtained can be advantageously used as synthesis intermediates, particularly in the so-called “green chemistryâ€? sector, or in the production of biofuels such as, for example, “biodieselâ€? or “green dieselâ€?, which can be used as such, or mixed with other fuel for transportation.

专利号:US-11617758-B2
优先权日:2009-12-31
标 题 :Emulsion formulations
发明人：DHINGRA OM; BERNSTEIN JAMES S
权利人:MARIUS PHARMACEUTICALS LLC
摘要:A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.